Investigational drug · Phase 3
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Actinic Keratosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride"
First trial start
2025
Nov 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride", any sponsor or status.
Conditions studied
As listed on its trial records.
- Actinic Keratosis
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride" as an intervention, largest first.
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper ExtremitiesPivotal-lookingRecruiting
Sun Pharmaceutical Industries, Inc.Industry
NCT07144852 · 260 participants (planned) · Start Nov 29, 2025 · Primary completion Jan 2027
Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% · For: Actinic Keratosis
Sites: Phoenix, Arizona; Fremont, California; Castle Rock, Colorado · 22 sites in all
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and ScalpPivotal-lookingRecruiting
Sun Pharmaceutical Industries, Inc.Industry
NCT07144345 · 160 participants (planned) · Start Nov 19, 2025 · Primary completion Jan 2027
Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% · For: Actinic Keratosis
Sites: Fremont, California; Aventura, Florida; Rolling Meadows, Illinois · 12 sites in all
Sun Pharmaceutical Industries LimitedIndustry
NCT07729579 · 48 participants (planned) · Start Aug 4, 2026 · Primary completion Dec 2026
Drug: Investigational drug · For: Actinic Keratosis (AK)
Sites: College Station, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Actinic Keratosis
- BimiralisibPhase 21 trial
TORQUR · Actinic Keratosis
- HW211026Phase 21 trial
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Actinic Keratosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.